Cart contains    items
SEARCH

  |
  |  
  |  
  |  
  |  
  |  
 
Browse by molecule: [A]  [B]  [C]  [D]  [E]  [F]  [G]  [H]  [I]  [J]  [K]  [L]  [M]  [N]  [O]  [P]  [Q]  [R]  [S]  [T]  [U]  [V]  [W]  [X]  [Y]  [Z]  

Human VEGFR2 Recombinant

VEGFR2

accession:  P35968
   Size A     50ug   $ 160
   Size B      200ug  $550
   Size C      1000ug  $ 2750
Domain  : 
Gene  :  VEGFR2
Catalog no. :  RKP35968

 

Source:

Optimized DNA sequence encoding mature chain of human Vascular endothelial growth factor receptor 2 (VEGFR2) (MET1-GLU764) including an C-terminal His tag was expressed in HEK293 cells.


 
Molecular weight:

Recombinant human VEGFR2 (FLK-1) is a protein consisting of 770 amino acid residue subunits,due to glycosylation migrates as an approximately 100kDa band protein on reduced SDS-PAGE.


 
Purity:
>95%, as determined by SDS-PAGE and HPLC
 
Endotoxin:
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).

 
Biological Activity:
The activity was tested by the ability to inhibit proliferation of HUVEC cells. The ED50 measured for this effect i 10-20 ng/ml

              
Presentation:
Recombinant  human Vascular endothelial growth factor receptor 2 (VEGFR2) is lyophilized  from 0.2 μm filtered PBS solution,  pH7.2 ,  5% Trehalose.

              
Reconstitution:
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

 
Storage:
Recombinant VEGFR2 (FLK-1) can be stored in working aliquots at 2° - 8° C for one month, or at -20°C to -70°C for twelve months.

Avoid repeated freeze/thaw cycles.

 
Usage:
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

 

VEGFR-2

VEGFR-2 is a member of a broader family of receptor tyrosine kinases consisting the VEGFR1, 2, and 3 also known as flt-1, KDR, and flt-4. This is a family of transmembrane tyrosine kinase receptors with 7 Ig domains. Ligands such as VEGF-A and placental growth factor bind the VEGFRs within immunoglobin-like domains 2 and 3, with domain 2 making the primary contact and domain 3 determining the specificity of binding.

Related Publications:
evidence for g-quadruplex in the promoter of VEGFR-2 and its targeting to inhibit tumor angiogenesis
Nucleic Acids Res., Dec 2013; 10.1093/nar/gkt1289.
lysine methylation promotes VEGFR-2 activation and angiogenesis
Sci. Signal., Dec 2013; 6: ra104.
a heterodimeric fc-based bispecific antibody simultaneously targeting VEGFR-2 and met exhibits potent antitumor activity
Mol. Cancer Ther., Dec 2013; 12: 2748 - 2759.
static, but not cyclic tensional forces on the heart increase anti-angiogenic sflt-1 expression in endothelial cells and inhibit VEGFR-2 activation
Eur. Heart J., Aug 2013; 34: P5665.
inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function
Diabetes, Aug 2013; 62: 2870 - 2878.




by class:
Cytokines
Chemokines
Growth factors
CD markers
Viral Antigens
Other
by species:
Human
mouse
Rat
Antibodies:
Purified Polyclonal
Related Products:
product_icon_8.jpg Mouse VEGFR2 Recombinant, Fc
product_icon_8.jpg Mouse VEGFR2 Recombinant
product_icon_8.jpg Human VEGFR2 Recombinant, Fc
product_icon_8.jpg Human VEGFR2 Recombinant
product_icon_7.jpg Rabbit anti VEGFR2 Polyclonal
 
 
 
Item name Size Quantity Price(USD) Remove
checkout
Cart Total $